<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05626504</url>
  </required_header>
  <id_info>
    <org_study_id>317314</org_study_id>
    <nct_id>NCT05626504</nct_id>
  </id_info>
  <brief_title>Outcome Study of the Pipeline Embolization Device With Vantage Technology in Unruptured Aneurysms</brief_title>
  <acronym>PEDVU</acronym>
  <official_title>Outcome Study of the Pipeline Embolization Device With Vantage Technology in Unruptured Aneurysms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King's College Hospital NHS Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>King's College Hospital NHS Trust</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this project the investigators study the safety and efficacy of the pipeline embolization&#xD;
      device with vantage technology in treatment of unruptured brain aneurysms&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 27, 2022</start_date>
  <completion_date type="Anticipated">March 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate 30-day morbidity rates</measure>
    <time_frame>Done at 30 days post procedural</time_frame>
    <description>We will evaluate short term clinical outcome in the form of morbidity rates 30 days after the procedure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate 30-day mortality rates</measure>
    <time_frame>Done at 30 days post procedural</time_frame>
    <description>We will evaluate short term clinical outcome in the form of mortality rates 30 days after the procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate 1-year morbidity rates</measure>
    <time_frame>Done at &gt;30days up to 1 year post procedural</time_frame>
    <description>We will evaluate long term clinical outcome in the form of morbidity rates &gt;30days up to 1 year after the procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate 1-year mortality rates</measure>
    <time_frame>Done at &gt;30days up to 1 year post procedural</time_frame>
    <description>We will evaluate long term clinical outcome in the form of mortality rates &gt;30days up to 1 year after the procedure</description>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Brain Aneurysm</condition>
  <condition>Intracranial Hemorrhages</condition>
  <condition>Stroke</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Pipeline Embolization Device with Vantage Technology</intervention_name>
    <description>Flow-diverter device occludes aneurysms through endoluminal reconstruction and remodelling of the parent artery.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients Treated with pipeline embolization devices during 2021 and 2022&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients treated with Pipeline Embolization Device with Vantage Technology (PEDV)&#xD;
&#xD;
          -  MRA and/or DSA (or tomographic angiography) available for follow up&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Insufficient background data available e.g., to determine size of aneurysm and&#xD;
             pipeline device&#xD;
&#xD;
          -  PEDV used for causes other than aneurysms, e.g., fistulas and dissection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kings College Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Booth</last_name>
      <phone>02032994828</phone>
      <email>thomasbooth@nhs.net</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Atasoy D, Kandasamy N, Hart J, Lynch J, Yang SH, Walsh D, Tolias C, Booth TC. Outcome Study of the Pipeline Embolization Device with Shield Technology in Unruptured Aneurysms (PEDSU). AJNR Am J Neuroradiol. 2019 Dec;40(12):2094-2101. doi: 10.3174/ajnr.A6314. Epub 2019 Nov 14.</citation>
    <PMID>31727754</PMID>
  </reference>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 1, 2022</study_first_submitted>
  <study_first_submitted_qc>November 22, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2022</study_first_posted>
  <last_update_submitted>November 22, 2022</last_update_submitted>
  <last_update_submitted_qc>November 22, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 23, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intracranial Hemorrhages</mesh_term>
    <mesh_term>Intracranial Aneurysm</mesh_term>
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

